

# IL-33 Antibody

Catalog # ASC10557

# **Product Information**

**Application** WB, IF, E **Primary Accession** 095760

Other AccessionNP\_254274, 15559209ReactivityHuman, Mouse, Rat

Host Rabbit
Clonality Polyclonal
Isotype IgG
Calculated MW 30759
Concentration (mg/ml) 1 mg/mL
Conjugate Unconjugated

**Application Notes** IL-33 antibody can be used for the detection of IL-33 by Western blot at 1 - 2

□g/mL. For immunofluorescence start at 20 □g/mL.

# **Additional Information**

**Gene ID** 90865

Other Names Interleukin-33, IL-33, Interleukin-1 family member 11, IL-1F11, Nuclear factor

from high endothelial venules, NF-HEV, Interleukin-33 (95-270), Interleukin-33

(99-270), Interleukin-33 (109-270), IL33, C9orf26, IL1F11, NFHEV

Target/Specificity IL33;

**Reconstitution & Storage** IL-33 antibody can be stored at 4°C for three months and -20°C, stable for up

to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high

temperatures.

**Precautions** IL-33 Antibody is for research use only and not for use in diagnostic or

therapeutic procedures.

## **Protein Information**

Name IL33 ( <u>HGNC:16028</u>)

**Synonyms** C9orf26, IL1F11, NFHEV

**Function** Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in

turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:<u>16286016</u>, PubMed:<u>19841166</u>). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2- associated cytokines

(PubMed:<u>17853410</u>, PubMed:<u>18836528</u>). Also involved in activation of mast cells, basophils, eosinophils and natural killer cells (PubMed:<u>17853410</u>, PubMed:<u>18836528</u>). Acts as an enhancer of polarization of alternatively

activated macrophages (PubMed:<u>19841166</u>). Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury (PubMed:<u>17853410</u>, PubMed:<u>18836528</u>). Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity).

#### **Cellular Location**

Nucleus. Chromosome. Cytoplasm Cytoplasmic vesicle, secretory vesicle Secreted Note=Secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore following cleavage by CELA1 (PubMed:35794369). Associates with heterochromatin and mitotic chromosomes (PubMed:17185418). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10; it results in protein translocation from the cytoplasm into the ERGIC (endoplasmic reticulum-Golgi intermediate compartment) followed by vesicle entry and secretion (PubMed:32272059).

#### **Tissue Location**

Expressed at high level in high endothelial venules found in tonsils, Peyer patches and mesenteric lymph nodes. Almost undetectable in placenta.

# **Background**


IL-33 Antibody: Interleukin-33 (IL-33) is a recently identified member of the IL-1 family of cytokines whose other members include IL-1 $\alpha$ /beta, IL-1Ra and IL-18. Its receptor has been shown to be ST2, an IL-1 receptor family member that also acts as a negative regulator of TLR-IL-1R signaling and IL-1R accessory protein (IL-1RAcP). Receptor binding of IL-33 activates NF- $\kappa$ B and MAP kinases and induces the expression of TH2-associated cytokines such as IL-4, IL-5 and IL-6. Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine. Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties.


### References

Schmitz J, Owyang A, Oldham E, et al. IL-33, and interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-90. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 2000; 11:483-6. Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 2004; 5:373-9. Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 2007; 179:2551-5.

# **Images**

Western blot analysis of IL-33 in human lymph node tissue lysate with IL-33 antibody at (A) 1 and (B) 2 µg/mL.





Immunofluorescence of IL-33 in Human Lymph Node tissue with IL-33 antibody at 20  $\mu\text{g/mL}.$ 

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.